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Abstract The effect of platelet stimulation on the subcellular
localization of CD38, a membrane glycoprotein that catalyses
the synthesis of cyclic ADP-ribose from L-NAD+ was investi-
gated. Treatment of human platelets with thrombin caused the
association of about 40% of the total ADP-ribosyl cyclase
activity with the cytoskeleton, through the translocation of the
CD38 molecule from the Triton X-100-soluble to the insoluble
fraction. The interaction of CD38 with the cytoskeleton was a
specific and reversible process, mediated by the binding to the
actin-rich filaments and was inhibited by treatment of platelets
with cytochalasin D. This event was regulated by integrin KIIbL3
and platelet aggregation as it was prevented by the inhibition of
fibrinogen binding and was not observed in platelets from a
patient affected by Glanzmann thrombasthenia. These results
demonstrate that the subcellular localization of CD38 can be
influenced by platelet stimulation with physiological agonists,
and that membrane CD38 can interact with intracellular
proteins.
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1. Introduction
CD38 is a type II transmembrane glycoprotein of 46 kDa
expressed in both hematopoietic and nonhematopoietic cells
[1]. Several studies have revealed a variety of functional prop-
erties of CD38, suggesting that this molecule may act as a
bifunctional ectoenzyme, an adhesion molecule or a cell-acti-
vating receptor. The extracellular domain of CD38 possesses
both ADP-ribosyl cyclase activity, able to synthesize cyclic
ADP-ribose (cADPR) from L-NAD, and cADPR hydrolase
activity, able to hydrolyse cADPR to ADP-ribose (ADPR)
[2]. cADPR is an intracellular second messenger that pro-
motes the release of Ca2 from speci¢c stores that are insen-
sitive to inositol 3,4,5-trisphosphate [3]. As CD38 is respon-
sible for the transient formation of cADPR, it has been
suggested that it could be involved in the regulation of Ca2
homeostasis.
CD38 may also function as an adhesion molecule, accord-
ing to its ability to bind to hyaluronate and to support the
interaction of lymphocytes with endothelial cells [4,5]. Re-
cently, a 120 kDa membrane glycoprotein able to interact
with CD38 has been identi¢ed in a variety of cells, including
endothelial cells, platelets, and monocytes [6].
Several reports showed that ligation of CD38 on the cell
surface by selected monoclonal antibodies elicited cellular re-
sponses including proliferation, production of cytokines, and
protection from apoptosis [7^9]. These ¢ndings suggest that
CD38 is a cell-activating receptor. Some features of the signal
transduction pathways activated by ligation of CD38 have
been elucidated and involve the rapid tyrosine phosphoryla-
tion of several intracellular signaling proteins including phos-
pholipase CQ, the phosphatidylinositol 3-kinase, the proto-on-
cogene Cbl, and the tyrosine kinases Syk and Btk [10^12].
We have recently demonstrated that enzymatically active
CD38 is expressed on the plasma membrane of human plate-
lets [13]. These cells are extremely reactive and can be rapidly
activated by a variety of physiological agonists involved in
haemostatic and in£ammatory processes [14]. One of the ear-
liest events following platelet stimulation is the reorganization
of the actin-based cytoskeleton [15]. This structure plays a
central role in the regulation of platelet morphology and cell
adhesion [16]. Moreover, the cytoskeleton represents an im-
portant network connecting several molecules involved in
platelet activation. For instance, some tyrosine kinases, like
pp60src, pp72syk and pp125FAK [17^19], lipid metabolizing en-
zymes, like phosphatidylinositol 3-kinase and phospholipase
C [20], phosphotyrosine phosphatases, like PTP1B [21], low
molecular weight GTP-binding proteins, like rap1b and rap2b
[22,23], and membrane glycoproteins, like integrin KIIbL3 and
PECAM-1 [24,25] interact with the actin ¢laments during
platelet aggregation.
In this work we show that thrombin, the most potent
platelet agonist, induces the interaction of enzymatically ac-
tive CD38 with the intracellular cytoskeleton, and that this
event is promoted by the binding to the actin ¢laments and
is regulated by the integrin KIIbL3.
2. Materials and methods
2.1. Materials
Nicotinamide guanine dinucleotide (NGD), cyclic GDP-ribose,
cytochalasin D, U46619, leupeptin, RGDS peptide, and K-thrombin,
were purchased from Sigma. The thrombin receptor-activating peptide
(TRAP) was from Calbiochem. Microcon 3 ¢lters were from Amicon.
Triton X-100 was from ICN. Sepharose 2B-CL and protein A-Sephar-
ose were from Pharmacia Biotech. The monoclonal antibody IB4
against CD38 was described elsewhere [7]. All other reagents were
of analytical grade.
2.2. Platelet preparation and cytoskeleton extraction
Human platelets were isolated by gel-¢ltration on a Sepharose 2B-
CL column, in HEPES bu¡er (10 mM HEPES, 137 mM NaCl,
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2.9 mM KCl, 12 mM NaHCO3, pH 7.4) as previously described [22].
Platelet samples (500 Wl, 1U109 platelets/ml) were prewarmed at 37‡C
and then treated with HEPES bu¡er or 10 nM thrombin, 10 Wg/ml
collagen, or 10 WM U46619 for 2 min. In some experiments, incuba-
tion with 10 WM cytochalasin D or 1 mM RGDS peptide for 2 min
was performed before stimulation of the samples. After cell lysis with
1% Triton X-100, platelet cytoskeleton was isolated as previously
described [22], and mechanically resuspended in 500 Wl of HEPES
bu¡er, pH 7.4 to measure the ADP-ribosyl cyclase activity.
2.3. Preparation of the polymerized actin-rich fraction
This was performed essentially as described [26], with some mod-
i¢cations. Brie£y, cytoskeleton from thrombin-stimulated platelets
was solubilized with 1 ml of bu¡er containing 0.6 M KI, 100 mM
PIPES, 100 mM KCl, 10 Wg/ml leupeptin, 1 mM PMSF, 100 WM
sodium ortho-vanadate, pH 6.5, for 50 min at 4‡C under gentle shak-
ing, and then centrifuged at 35 000Ug for 30 min at 4‡C. The super-
natant (KI-soluble) was collected and dialyzed overnight at 4‡C with
1 l of bu¡er containing 10 mM PIPES, 1 mM EGTA, 2 mM MgCl2,
1 mM PMSF, 100 WM sodium ortho-vanadate, pH 6.8. The insoluble
material, containing the repolymerized actin and actin-binding pro-
teins, was recovered by centrifugation at 13 000Ug for 5 min at 4‡C,
washed twice with dialysis bu¡er, and ¢nally resuspended in HEPES
bu¡er, pH 7.4.
2.4. Immunoprecipitation
Cytoskeletal samples from thrombin-activated platelets were me-
chanically resuspended with 500 Wl of HEPES bu¡er, pH 7.4, contain-
ing 1% Triton X-100, 5 mM EGTA, 2 mM PMSF, 10 Wg/ml leupep-
tin, using a micropipette. The insoluble material was discarded by
centrifugation at 13 000Ug for 10 min, and the soluble fraction was
immunoprecipitated with 3 Wg of the anti-CD38 monoclonal antibody
IB4, or 3 Wg of mouse IgG as previously described [13]. Immunopre-
cipitates were then resuspended in HEPES bu¡er, pH 7.4, and tested
for the ADP-ribosyl cyclase activity.
2.5. Enzymatic analysis
The ADP-ribosyl cyclase activity was measured as previously de-
scribed [13], using NGD instead of NAD as a substrate for CD38,
because the synthesized product, the cyclic GDP-ribose (cGDPR),
which is the guanine nucleotide equivalent to cADPR, is only a
poor substrate for the cADPR hydrolase activity of the enzyme,
and accumulates in the medium [27,4]. Samples were prewarmed at
37‡C for 5 min, and then incubated with 100 WM NGD. Aliquots
(100 Wl) were withdrawn immediately after the addition of the nucleo-
tide substrate, and after incubation at 37‡C for 60 min, and centri-
fuged at 13 000Ug for 5 min. The supernatants were ultra¢ltered on
Microcon 3 membrane (cut-o¡ 3000 Da), and then analyzed by re-
verse phase HPLC using a 25U0.46 cm Supelcosil LC-18T column as
described [13].
3. Results
The interaction of the CD38 molecule with the cytoskeleton
was investigated by measuring the ADP-ribosyl cyclase activ-
ity in the Triton X-100-insoluble material prepared from rest-
ing and stimulated platelets. While very little ADP-ribosyl
cyclase activity was detected in the cytoskeleton from resting
platelets (1.4 þ 1.1 pmoles/min), a signi¢cant amount of
cGDPR (16.0 þ 6.7 pmoles/min) was produced from NGD
by the cytoskeleton obtained from thrombin-stimulated plate-
lets (Fig. 1). By contrast, stimulation of platelets with collagen
and the thromboxane A2 analogue, U46619, promoted only a
slight increase of the ADP-ribosyl cyclase activity recovered in
the Triton X-100-insoluble material (2.8 þ 2.0 and 2.4 þ 1.6
pmoles/min, respectively) (Fig. 1). By analysing the ADP-ri-
bosyl cyclase activity in resting intact platelets incubated with
NGD, we measured the production of 37.8 þ 2.9 pmoles/min
of cGDPR. Therefore, we calculated that, in the absence of
stimulation, only 3.7% ( þ 2.9%, S.D.) of the total ADP-ribo-
syl cyclase activity was associated with the cytoskeleton. This
amount increased to 42.3% ( þ 17.6%, S.D.), 7.4% ( þ 5.3%,
S.D.), and 6.3% ( þ 4.2%, S.D.) upon platelet stimulation
with thrombin, collagen, and U46619, respectively.
We next focused our investigations on the e¡ect of throm-
bin, and we analyzed whether the agonist-induced increase of
the production of cGDPR by the cytoskeleton was due to the
stimulation of the preexisting activity or to the association of
more enzyme with the Triton X-100-insoluble material. We
compared the ADP-ribosyl cyclase activity in the cytoskeleton
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Fig. 1. Association of the ADP-ribosyl cyclase activity with the
platelet cytoskeleton. Gel-¢ltered platelets were stimulated with
10 nM thrombin, 10 Wg/ml collagen, 10 WM U46619, or bu¡er
(basal), and the Triton X-100-insoluble materials were prepared and
incubated with 100 WM NGD for 60 min. Results are expressed as
pmoles/min of cGDPR produced by the cytoskeleton (csk) isolated
from 108 platelets, and represent the means þ S.D. of three to seven
separated experiments.
Fig. 2. Analysis of the ADP-ribosyl cyclase activity in platelet sub-
cellular fractions. Gel-¢ltered platelets were treated with either
bu¡er (basal) or 10 nM thrombin (thrombin) for 2 min at 37‡C,
and then lysed with Triton X-100 (1% ¢nal concentration). Lysed
samples were centrifuged and the Triton X-100-soluble (TS) and in-
soluble (CSK) fractions were separated and incubated with 100 WM
NGD for 60 min. The production of cGDPR by each fraction was
determined by HPLC analysis. Results are expressed as pmoles/min
of cGDPR produced by the subcellular fraction prepared from 108
platelets, and represent the means þ S.D. of ¢ve di¡erent experi-
ments.
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and in the Triton X-100-soluble fraction from resting and
thrombin-stimulated platelets. As shown in Fig. 2, the in-
crease of cGDPR production by the cytoskeleton induced
by thrombin was paralleled by a decreased production of
this nucleotide by the Triton X-100-soluble material, suggest-
ing a translocation rather than a stimulation of the ADP-
ribosyl cyclase activity.
To demonstrate that the ADP-ribosyl cyclase activity asso-
ciated with the cytoskeleton from thrombin-stimulated plate-
lets was really due to the CD38 molecule, cytoskeletal samples
from thrombin-activated platelets were solubilized and immu-
noprecipitated with the monoclonal antibody IB4, speci¢c for
CD38, or with control mouse immunoglobulins. We found
that the immunoprecipitates obtained with the anti-CD38
monoclonal antibody IB4, but not with control mouse immu-
noglobulins, were able to immunoprecipitate a signi¢cant
amount of ADP-ribosyl cyclase activity from the cytoskeleton
of thrombin-activated platelets, corresponding to a produc-
tion of 8.74 þ 1.48 pmoles/min of cGDPR.
We then analyzed the e¡ect of cytochalasin D, a potent
inhibitor of actin polymerization on the thrombin-induced
association of CD38 with the cytoskeleton. We had previously
shown that treatment of intact platelets with 10 WM cytocha-
lasin D for 2 min did not a¡ect platelet aggregation induced
by thrombin, but completely prevented the agonist-induced
actin polymerization [28]. As shown in Fig. 3, cytochalasin
D almost completely inhibited the thrombin-induced associa-
tion of ADP-ribosyl cyclase activity with the cytoskeleton. To
test the possible direct interaction of CD38 with the actin
¢laments system of the cytoskeleton, a repolymerized actin-
rich fraction was prepared from the Triton X-100-insoluble
material of thrombin-stimulated platelets as described in Sec-
tion 2, and tested for the ADP-ribosyl cyclase activity. As
shown in Fig. 4, the ADP-ribosyl cyclase activity present in
the Triton X-100-insoluble material was also recovered in the
repolymerized actin fraction, indicating that CD38 directly
interacts with actin or associates to actin-binding proteins.
It is known that the interaction of several signaling mole-
cules and membrane glycoproteins with the cytoskeleton is
regulated by integrin KIIbL3 engagement and platelet aggrega-
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Fig. 3. E¡ect of cytochalasin D on the association of CD38 with
the cytoskeleton. Gel-¢ltered platelets were incubated at 37‡C in the
presence or in the absence of 10 WM cytochalasin D (cytD) for
2 min, and then treated with bu¡er (basal), or 10 nM thrombin
(thrombin) for 2 min. The cytoskeleton from each sample was pre-
pared and tested for the ADP-ribosyl cyclase activity of CD38 as
described in Section 2. Results are the means þ S.D. of three to sev-
en di¡erent experiments.
Fig. 4. CD38 interacts with the actin ¢laments. Triton X-100-insolu-
ble material from thrombin-stimulated platelets (A) and actin-rich
¢laments (B), prepared by solubilization of the Triton X-100-insolu-
ble material with KI followed by induction of actin repolymeriza-
tion as described in Section 2, were incubated with 100 WM NGD,
and the production of cGDPR was analyzed by HPLC. Typical
chromatographic pro¢les of the aliquots of the samples processed
immediately after the addition of the substrate (broken lines), or
after 60 min of incubation (unbroken lines) are reported. The re-
duced activity of the repolymerized fraction (9.2 þ 2.8 pmoles
cGDPR/min) compared to that of the Triton X-100-insoluble mate-
rial (16.0 þ 6.7 pmoles cGDPR/min) may re£ect the fact that some
unpolymerized actin persists even after dialysis of the KI-soluble
material. Results are representatives of at least three di¡erent ex-
periments.
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tion [17^25]. For this reason, we measured the ADP-ribosyl
cyclase activity in the cytoskeleton of platelets stimulated with
thrombin in the presence of 1 mM RGDS peptide, which
inhibits both ¢brinogen binding and platelet aggregation, or
in the absence of stirring, a treatment that allows ¢brinogen
binding but prevents platelet aggregation. Moreover, we ana-
lyzed platelets from a patient a¡ected by Glanzmann throm-
basthenia, which lack the integrin KIIbL3 and fail to aggregate.
As shown in Fig. 5, inhibition of both ¢brinogen binding and
platelet aggregation prevented the thrombin-induced interac-
tion of CD38 with the cytoskeleton. Fig. 5 also shows that the
ADP-ribosyl cyclase activity was not detected in the cytoskel-
eton of thrombasthenic platelets stimulated with thrombin.
4. Discussion
Human platelets express enzymatically active CD38 on the
plasma membrane [13], and can be activated by a variety of
extracellular agonists that lead to shape change, secretion, and
aggregation [14]. One of the more important e¡ects of platelet
activation is the reorganization of the intracellular cytoskele-
ton, which is not only responsible for the morphological
changes of activated platelets, but also represents a functional
network connecting several signaling molecules and mem-
brane glycoproteins [15,17^25]. In this work, we showed
that a little ADP-ribosyl cyclase activity was associated with
the cytoskeleton in resting platelets, and that stimulation with
the strong agonists, thrombin, collagen, and the thromboxane
A2 analogue U46619, induced an increase of the ability of the
cytoskeleton to produce cGDPR from NGD. This e¡ect was
particularly evident in platelets stimulated with thrombin,
where about 40% of the ADP-ribosyl cyclase activity ex-
pressed by resting intact platelets was recovered with the Tri-
ton X-100-insoluble material. We also found that the e¡ect of
thrombin was totally mediated by the activation of its mem-
brane receptor, as identical results were obtained using the
thrombin receptor-activating peptide, TRAP (data not
shown). Moreover, immunoprecipitation experiments demon-
strated that the ADP-ribosyl cyclase activity in the cytoskele-
ton was actually due to the CD38 molecule.
In thrombin-stimulated platelets, the increase of the ADP-
ribosyl cyclase activity in the cytoskeleton was concomitant
with the reduction of the same activity in the Triton X-100-
soluble fraction. Moreover, the sum of the ADP-ribosyl cy-
clase activity in the two fractions prepared from activated cells
was identical to that of resting cells, and we did not measure
any increase in the speci¢c ADP-ribosyl cyclase activity (as
pmoles of cGDPR/min/mg of proteins) in the subcellular frac-
tions analyzed (data not shown). Therefore, we conclude that
thrombin induced a real redistribution of the CD38 molecules
in activated platelets, rather than the stimulation of the activ-
ity of the CD38 molecules already associated with the cyto-
skeleton.
We found that the translocation of CD38 to the cytoskele-
ton in thrombin-stimulated platelets required actin polymer-
ization, since it was almost completely prevented by cytocha-
lasin D, and was a reversible and speci¢c process mediated by
the interaction of the enzyme with the actin ¢laments or with
some actin-binding proteins. This is demonstrated by the evi-
dence that cytoskeletal CD38 was solubilized when actin ¢la-
ments were selectively depolymerized, and spontaneously re-
associated with actin when repolymerization was induced ‘in
vitro’. In addition to actin polymerization, the association of
CD38 with the cytoskeleton also required ¢brinogen binding
to the integrin KIIbL3 and platelet aggregation, as it was pre-
vented by the RGDS peptide and by the omission of stirring,
and was not observed in platelets from a patient a¡ected by
Glanzmann thrombasthenia. In this regard, thus, CD38 be-
haves like other signaling enzymes, whose association with the
cytoskeleton is dependent on integrin engagement [17,20,21].
The association of CD38 with the cytoskeleton in throm-
bin-stimulated platelets may play multiple roles. One of the
most intriguing questions about the cellular function of this
molecule rises from the evidence that the product of its enzy-
matic activity, the cADPR, supposed to act as an intracellular
second messenger involved in the regulation of Ca2 release, is
produced outside the cell. In this contest, it is possible that the
association with the actin ¢laments represents a way to medi-
ate the internalization of the enzymatically active CD38. It is
also possible that the interaction of CD38 with the cytoskele-
ton results in a relocation of the enzyme in a suitable mem-
brane environment to promote the in£ux of the produced
cyclic nucleotide into the cell. In addition, it has been shown
that ligation of CD38 on cell surface initiates transmembrane
signaling processes leading to tyrosine phosphorylation of sev-
eral proteins. Since in aggregated platelets the cytoskeleton
represents a network connecting several signaling molecules,
including the tyrosine kinases pp60src, pp72syk and pp125FAK
[17^19], the translocation of CD38 molecule described in the
present work may represent a way to link this membrane
glycoprotein to intracellular e¡ectors.
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Fig. 5. Role of integrin KIIbL3 and platelet aggregation on the trans-
location of CD38 to the cytoskeleton. Normal platelets were incu-
bated at 37‡C in the absence or in the presence of 1 mM RGDS
peptide. Samples were then treated with bu¡er (basal) or with 10
nM thrombin. In one sample, stirring was omitted. Platelets from a
patient a¡ected by Glanzmann thrombasthenia (GT) were stimu-
lated with 10 nM thrombin for 2 min under constant stirring. Cy-
toskeletons were prepared and the ADP-ribosyl cyclase activity was
tested using NGD as substrate. Results with normal platelets are
the means þ S.D. of three to seven experiments. Analysis of throm-
basthenic platelets was performed in duplicate.
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(MURST, Progetti di Ricerca di Interesse Nazionale), and Consiglio
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